Research Investigator II

The successful candidate will demonstrate clear and professional verbal and written communication, capable of presenting scientific results to multidisciplinary teams, senior management and at external scientific meetings. The candidate will contribute to the development of external partnerships/collaborations to advance internal programs and the understanding of the interplay between tumor genetics/biology and anti-tumor immune responses as well as publish to advance our science and support our scientific reputation. As a highly matrixed working group, the individual should demonstrate the ability to contribute to various projects outside of his/her own, as appropriate, and collaborate with stakeholders from all relevant and necessary functions within BMS as well as external collaborators. S/he will keep up-to-date in the literature related to his/her field, act as an expert resource in his/her scientific field and in related disciplines.

Qualifications

Required:

• A Ph.D. degree with post-doctoral/academic/industrial experience in cancer biology and genetics or a closely related field
• A proven track record in the field of cancer biology and genetics, as evidenced by publication record
• Excellent in vitro biology skills, experimental design and execution, as well as expertise to independently apply bioinformatics and data mining through multi-variate analysis
• Ability to effectively interact with core bioinformatics colleagues, as well as to use desktop tools/interfaces (e.g., Oncoland, Wuxi) and public databases (CBIO, Achilles, etc.)
• Excellent interpersonal skills with the ability to interact and influence effectively with people, internally and externally, is required.
• Experience in the design, validation and execution of genetic and/or phenotypic screens is desired.
• The ability to manage a small laboratory group is expected, including providing from growth and development opportunities for associates reports.
• This position is located in Cambridge, MA. There will be less than 10% travel.